For patients who had an EGFR or ALK test, irrespective of NSCLC histology, the median OS (95% CI) from initiation of first-line therapy ranged in months from 10.0 (7.4–12.6) in Japan to 26.7 (22.7–34.7) in Taiwan. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.